Paul Celano

TL;DR: Addition of trastuzumab to carboplatin-paclitaxel was well tolerated and increased progression-free survival, and no unexpected safety signals emerged.

TL;DR: Addition of T to C/P increased PFS and OS in women with advanced/recurrent HER2/Neu-positive USC, with the greatest benefit seen for the treatment of stage III to IV disease.

TL;DR: Belinostat, carboplatin, and paclitaxel combined was reasonably well tolerated and demonstrated clinical benefit in heavily-pretreated patients with EOC.

TL;DR: Although women treated with CT had similar recurrence rates as those treated with OBS or RT, treatment with adjuvant chemotherapy may decrease the risk of extra-pelvic recurrence and improve survival.

TL;DR: The strongest evidence of benefit with docetaxel is in men with de novo high-volume (CHAARTED criteria) metastatic disease, and similar survival benefits are seen using abiraterone acetate in high-risk patients and in the metastatic population in STAMPEDE.